ReviewFrontiers in immunology2026
Pituitary adenylate cyclase-activating polypeptide and mitochondrial homeostasis in neuronal injury: mechanisms and translational prospects.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenylate cyclase-activating peptide (PACAP) is a pleiotropic neuropeptide widely distributed in the nervous system, exhibiting potent cytoprotective effects across a spectrum of neurological disorders. Its neuroprotection is largely mediated through three G protein-coupled receptors (PAC1, VPAC1, VPAC2), activating downstream pathways that converge on preserving mitochondrial integrity. Mitochondrial dysfunction, characterized by bioenergetic failure, oxidative stress, perturbed dynamics (such as fusion and fission), and impaired quality control, is a hallmark of traumatic nerve injury, cerebral ischemia, and retinal neuropathy. This review systematically synthesizes recent evidence elucidating how PACAP counteracts these pathological processes. We detail its mechanisms in 1) mitigating neuropathic pain and promoting axonal regeneration after peripheral nerve trauma; 2) attenuating excitotoxicity, apoptosis, and neuroinflammation following cerebral ischemia by regulating mitochondrial permeability, fission/fusion balance, and NLRP3 inflammasome activation; and 3) protecting retinal ganglion cells against diabetic retinopathy and glaucomatous damage via modulating oxidative stress and apoptotic signaling. Furthermore, we discuss the translational potential of PACAP, including its biomarker value in cerebrospinal fluid and plasma for injury prognosis, and the promise of innovative delivery routes to enhance brain bioavailability. By focusing on mitochondrial-centric mechanisms, this review underscores PACAP as a neuroprotective regulator and highlights its candidacy for developing next-generation neurotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.